These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16929495)

  • 21. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change.
    Franco EL; Mahmud SM; Tota J; Ferenczy A; Coutlée F
    Arch Med Res; 2009 Aug; 40(6):478-85. PubMed ID: 19853188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human papillomavirus type-distribution in condylomata acuminata of mainland China: a meta-analysis.
    Wang H; Qiao YL
    Int J STD AIDS; 2008 Oct; 19(10):680-4. PubMed ID: 18824620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HPV DNA testing for cervical cancer screening. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.
    Wright TC
    Int J Gynaecol Obstet; 2006 Nov; 95 Suppl 1():S239-46. PubMed ID: 17161163
    [No Abstract]   [Full Text] [Related]  

  • 24. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study.
    McGregor S; Saulo D; Brotherton JML; Liu B; Phillips S; Skinner SR; Luey M; Oliver L; Stewart M; Tabrizi SN; Garland S; Kaldor JM
    Vaccine; 2018 Jul; 36(29):4311-4316. PubMed ID: 29880245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The HPV test in cervical screening: a brave new world?
    Desai MS; Cubie HA
    Cytopathology; 2005 Feb; 16(1):3-6. PubMed ID: 15859308
    [No Abstract]   [Full Text] [Related]  

  • 26. Human papillomavirus in young women with Chlamydia trachomatis infection 7 years after the Australian human papillomavirus vaccination programme: a cross-sectional study.
    Chow EP; Danielewski JA; Fehler G; Tabrizi SN; Law MG; Bradshaw CS; Garland SM; Chen MY; Fairley CK
    Lancet Infect Dis; 2015 Nov; 15(11):1314-23. PubMed ID: 26201300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonavalent HPV vaccine (HPV-9): analysis of pre-registration data.
    Mariani L; Cristoforoni P; Perino A; Stigliano CM; Preti M
    Minerva Ginecol; 2016 Oct; 68(5):620-1. PubMed ID: 27430201
    [No Abstract]   [Full Text] [Related]  

  • 28. [Expert consensus on immunoprophylaxis of human papillomavirus-related diseases (abridged)].
    Vaccine and Immunization Branch, Chinese Preventive Medicine Association
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Dec; 53(12):1218-1235. PubMed ID: 31795578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of human papillomavirus vaccination on racial/ethnic disparities in vaccine-type human papillomavirus prevalence among 14-26 year old females in the U.S.
    Hirth J; McGrath CJ; Kuo YF; Rupp RE; Starkey JM; Berenson AB
    Vaccine; 2018 Nov; 36(50):7682-7688. PubMed ID: 30377066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HPV testing and vaccination in Europe.
    Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
    J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low prevalence of high-risk HPV in older women not attending organized cytological screening: a pilot study.
    Wikström I; Stenvall H; Wilander E
    Acta Derm Venereol; 2007; 87(6):554-5. PubMed ID: 17989903
    [No Abstract]   [Full Text] [Related]  

  • 32. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Not Available].
    Bode-Lesniewska B; Caduff R
    Praxis (Bern 1994); 2017; 106(6):305-310. PubMed ID: 28300000
    [No Abstract]   [Full Text] [Related]  

  • 34. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HPV infections and cytologic abnormalities in vaccinated women 21-34 years of age: Results from the baseline phase of the Onclarity trial.
    Wright TC; Parvu V; Stoler MH; Kodsi S; Eckert K; Yanson K; Cooper CK
    Gynecol Oncol; 2019 May; 153(2):259-265. PubMed ID: 30853359
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural history of HPV infections.
    Wright TC
    J Fam Pract; 2009 Sep; 58(9 Suppl HPV):S3-7. PubMed ID: 19744423
    [No Abstract]   [Full Text] [Related]  

  • 37. HPV screening offers greater protection against invasive cervical cancer than cytology, finds analysis.
    Kmietowicz Z
    BMJ; 2013 Nov; 347():f6624. PubMed ID: 24191217
    [No Abstract]   [Full Text] [Related]  

  • 38. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.
    Smith JS; Backes DM; Hoots BE; Kurman RJ; Pimenta JM
    Obstet Gynecol; 2009 Apr; 113(4):917-924. PubMed ID: 19305339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Declines in Prevalence of Human Papillomavirus Vaccine-Type Infection Among Females after Introduction of Vaccine - United States, 2003-2018.
    Rosenblum HG; Lewis RM; Gargano JW; Querec TD; Unger ER; Markowitz LE
    MMWR Morb Mortal Wkly Rep; 2021 Mar; 70(12):415-420. PubMed ID: 33764964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HPV vaccination and cancer prevention.
    Athanasiou A; Bowden S; Paraskevaidi M; Fotopoulou C; Martin-Hirsch P; Paraskevaidis E; Kyrgiou M
    Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():109-124. PubMed ID: 32284298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.